Myricx Bio
Developing a new class of ADCs based on NMT inhibition to treat cancer
About Myricx Bio
Myricx Bio is a UK-based biotech company that is working on discovering and developing a new type of treatment for cancer. They focus on creating drugs that use inhibitors of N-Myristoyltransferases (NMT) for antibody-drug conjugates (ADCs).
Legal Name
: Myricx Bio
Headquarters
: London, UK
Business Model
:
Founding Date
: 1970
No. of Employees
:
Founding Members
Related Post
Myricx Funding News – Myricx Bio Secures £90m Series A Funding to Advance Novel NMTi-ADC Therapeutics into Clinical Development
Startups Hit €100 million+ in 2024 Funding Report
Series A Funding NEWS Europe – July 2024
Biotech
Astraveus
They build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies.
Novartis
Rethink medicine to help people live longer and healthier lives, giving patients, doctors, and communities the tools they need to face serious illnesses with confidence.
Contact us: contact@startuprise.co.uk